Expression of eNOS3 and ve-cadherin in microvascular endothelium at 7-days of reperfused acute myocardial infarction

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 2, 2009, Pages 107-117

  Kang, Sheng ^a   Yang, Yue Jin ^b   Wang, Qing Zhi ^b   Li, Yue ^b   Tian, Yi ^b   Cheng, Yu Tong ^b  

^a TONGJI UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; VASCULAR ENDOTHELIAL CADHERIN; CADHERIN; LEUKOCYTE ANTIGEN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE EXPRESSION; HEART HEMODYNAMICS; HEART MUSCLE REPERFUSION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; LASER MICROSCOPY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MICROVASCULATURE; MINIPIG; MUSCLE TISSUE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; GENETICS; HEART INFARCTION; IN VITRO STUDY; METABOLISM; PATHOLOGY; SWINE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; CADHERINS; ENDOTHELIUM, VASCULAR; MICROVESSELS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; NITRIC OXIDE SYNTHASE TYPE III; RNA, MESSENGER; SWINE; SWINE, MINIATURE;

EID: 68349091661     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909788488663     Document Type: Article

References (43)

1. Reffelmann, T.; Kloner, R.A. The "no-reflow" phenomenon: basic science and clinical correlates. Heart, 2002, 87, 162-8.
2. Iwakura, K.; Ito, H.; Kawano, S.; Okamura, A.; Kurotobi, T.; Date, M.; Inoue, K.; Fujii, K. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur. Heart J., 2006, 27, 534-9.
3. Loscalzo, J.; Welch, G. Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis., 1995, 38, 87-104.
4. Michel, T.; Feron, O. Nitric oxide synthases: which, where, how, and why? J. Clin. Invest., 1997, 100, 2146-52.
5. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-6.
6. Kubes, P.; Suzuki, M.; Granger, D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA, 1991, 88, 4651-5.
7. Groves, P.H.; Lewis, M.J.; Cheadle, H.A.; Penny, W.J. SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty. Circulation, 1993, 87, 590-7.
8. Radomski, M.W.; Palmer, R.M.; Moncada, S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol., 1987, 92, 639-46.
9. Kubes, P.; Granger, D.N. Nitric oxide modulates microvascular permeability. Am. J. Physiol., 1992, 262, H611-5.
10. Garg, U.C.; Hassid, A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest., 1989, 83, 1774-7.
11. Garcia-Dorado, D.; Oliveras, J. Myocardial oedema: a preventable cause of reperfusion injury? Cardiovasc. Res., 1993, 27, 1555-63.
12. Lum, H., Roebuck, K.A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell Physiol., 2001, 280, C719-41.
13. Lander, H.M. An essential role for free radicals and derived species in signal transduction. FASEB J., 1997, 11, 18-24.
14. Natarajan, V. Oxidants and signal transduction in vascular endothelium. J. Lab. Clin. Med., 1995, 125, 26-37.
15. Gumbiner, B.M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell, 1996, 84, 345-57.
16. Hinck, L.; Näthke, I.S.; Papkoff, J.; Nelson, W.J. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J. Cell Biol., 1994, 125, 1327-40.
17. Nieset, J.E.; Redfield, A.R.; Jin, F.; Knudsen, K.A.; Johnson, K.R.; Wheelock, M.J. Characterization of the interactions of alphacatenin with alpha- actinin and beta-catenin/plakoglobin. J. Cell Sci., 1997, 110, 1013-22.
18. Navarro, P.; Caveda, L.; Breviario, F.; Mândoteanu, I.; Lampugnani, M.G.; Dejana, E. Catenin-dependent and - independent functions of vascular endothelial cadherin. J. Biol. Chem., 1995, 270, 30965-72.
19. Takeichi, M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu. Rev. Biochem., 1990, 59, 237-52.
20. Breviario, F.; Caveda, L.; Corada, M.; Martin-Padura, I.; Navarro, P.; Golay, J.; Introna, M.; Gulino, D.; Lampugnani, M.G.; Dejana, E. Functional properties of human vascular endothelial cadherin (7B4/ cadherin-5), an endothelium-specific cadherin. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1229-39.
21. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-54.
22. Loscalzo, J. Nitric oxide and vascular disease. N. Engl. J. Med., 1995, 333, 251-3.
23. Emerson, M.; Momi, S.; Paul, W.; Alberti, P.F.; Page, C.; Gresele, P. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb. Haemost., 1999, 81, 961-6.
24. Pluta, R.M.; Rak, R.; Wink, D.A.; Woodward, J.J.; Khaldi, A.; Oldfield, E.H.; Watson, J.C. Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury. Neurosurgery, 2001, 48, 884-92.
25. De, Caterina, R.; Libby, P.; Peng, H.B.; Thannickal, V.J.; Rajavashisth, T.B.; Gimbrone, MA, Jr.; Shin, WS.; Liao, J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest., 1995, 96, 60-8.
26. Ishida, A.; Sasaguri, T.; Kosaka, C.; Nojima, H.; Ogata, J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide- generating vasodilator in vascular smooth muscle cells. J. Biol. Chem., 1997, 272, 10050-7.
27. Kawashima, S.; Yamashita, T.; Ozaki, M.; Ohashi, Y.; Azumi, H.; Inoue, N.; Hirata, K.; Hayashi, Y.; Itoh, H.; Yokoyama, M. Endothelial NO synthase overexpression inhibits lesion formation in mouse model of vascular remodeling. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 201-7.
28. Moroi, M.; Zhang, L.; Yasuda, T.; Virmani, R.; Gold, H.K.; Fishman, M.C.; Huang, P.L. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J. Clin. Invest., 1998, 101, 1225-32.
29. Huang, Z.; Huang. P.L.; Ma, J.; Meng, W.; Ayata, C.; Fishman, M.C.; Moskowitz, M.A. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow. Metab., 1996, 16, 981-7.
30. Dejana, E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J. Clin. Invest., 1996, 98, 1949-53.
31. Corada, M.; Mariotti, M.; Thurston, G.; Smith, K.; Kunkel, R.; Brockhaus, M.; Lampugnani, MG.; Martin-Padura, I.; Stoppacciaro, A.; Ruco, L.; McDonald, D.M.; Ward, P.A.; Dejana, E. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc. Natl. Acad. Sci. USA, 1999, 96, 9815-20.
32. Petzelbauer, P.; Zacharowski, PA.; Miyazaki, Y.; Friedl, P.; Wickenhauser, G.; Castellino, F.J.; Gröger, M.; Wolff, K.; Zacharowski, K. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat. Med., 2005, 11, 298-304.
33. Pearson, J.D. Normal endothelial cell function. Lupus, 2000, 9, 183-8.
34. Pearson, J.D. Endothelial cell function and thrombosis. Baillieres. Best. Pract. Res. Clin. Haematol., 1999, 12, 329-41.
35. Minami, T.; Sugiyama, A.; Wu, S.Q.; Abid, R.; Kodama, T.; Aird, W.C. Thrombin and phenotypic modulation of the endothelium. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 41-53.
36. Brouland, J.P.; Egan, T.; Roussi, J.; Bonneau, M.; Pignaud, G.; Bal, C.; Vaiman, M.; André, P.; Hervé, P.; Mazmanian, G.M.; Drouet, L. In vivo regulation of von willebrand factor synthesis: von Wille-brand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 3055-62.
37. Ware, R.E.; Parker, R.I.; McKeown, L.P.; Graham, M.L. A human chimera for von Willebrand disease following bone marrow transplantation. Am. J. Pediatr. Hematol. Oncol., 1993, 15, 338-42.
38. Blann, A.D.; Farrell, A.; Picton, A.; McCollum, C.N. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease. Thromb. Res., 2000, 97, 209-16.
39. Mulvihill, N.; Foley, J.B.; Ghaisas, N.; Murphy, R.; Crean, P.; Walsh, M. Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. Am. J. Cardiol., 1999, 83, 1265-7, A9.
40. Mulvihill, N.T.; Foley, J.B.; Murphy, R.T.; Curtin, R.; Crean, P.A.; Walsh, M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart, 2001, 85, 623-7.
41. Collet, J.P.; Montalescot, G.; Vicaut, E.; Ankri, A.; Walylo, F.; Lesty, C.; Choussat, R.; Beygui, F.; Borentain, M.; Vignolles, N.; Thomas, D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation, 2003, 108, 391-4.
42. Soskin, P.; Mossard, J.M.; Arbogast, R.; Wiesel, M.L.; Grunebaum, L.; Roul, G.; Bareiss, P.; Moulichon, M.E.; Cazenave, J.P.; Sacrez, A. Variation in von Willebrand's Factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications. Eur. Heart J., 1994, 15, 479-82.
43. Ray, K.K.; Morrow, D.A.; Gibson, C.M.; Murphy, S.; Antman, E.M.; Braunwald, E. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur. Heart J., 2005, 26, 440-6.